Home › NDC Lookup › RxCUI directory › RxCUI 2689139

Terazosin 1 MG/ML Oral Solution [Tezruly] — RxCUI 2689139

RxNorm drug concept · Semantic branded drug
RxCUI 2689139 Semantic branded drug · SBD ● Current RxNorm concept 1 FDA product 1 package NDC Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI2689139
Official nameTerazosin 1 MG/ML Oral Solution [Tezruly]
Concept typeSemantic branded drug (SBD)
RxNorm statusCurrent RxNorm concept
Also known asTezruly 1 MG/ML Oral Solution; Tezruly 1 MG (equivalent to terazosin hydrochloride 1.1 MG) per ML Oral Solution
FDA products mapped1
Package NDCs mapped1
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Terazosin: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • It treats symptoms of an enlarged prostate (BPH) and high blood pressure. Your prescriber will tell you which one you are taking it for.
  • The first dose can drop your blood pressure and cause dizziness or fainting. Taking it at bedtime lowers the chance of an injury. Avoid driving or hazardous tasks for 12 hours afte...
  • Why do I take the first dose at bedtime?
  • Do not just jump back to your usual dose. After more than a few days off, the label says to restart with the starting regimen. Call your prescriber or me for guidance.
📖 Read our full Terazosin guide →

🕸️ Concept Web — How Terazosin 1 MG/ML Oral Solution [Tezruly] Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Terazosin 1 MG/ML Oral Solution [Tezruly] RxCUI 2689139

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 1

    The active substance itself — no strength, form, or brand attached yet.

    • Terazosin 37798
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Tezruly 2689134
  3. Dose forms 9

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Terazosin Oral Solution 2689132
    • Terazosin Oral Liquid Product 2689131
    • Terazosin Oral Product 1164232
    • Terazosin Oral Solution [Tezruly] 2689138
    • Tezruly Oral Liquid Product 2689137
    • Tezruly Oral Product 2689136
    • Oral Solution 316968
    • Oral Liquid Product 1151137
    • +1 more in this family
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 13 of 14 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Terazosin 1 MG/ML Oral Solution SCD · 2689133
  • Terazosin 1 MG/ML SCDC · 2689130
  • Terazosin Oral Solution SCDF · 2689132
  • Terazosin Oral Liquid Product SCDG · 2689131
  • Terazosin Oral Product SCDG · 1164232

Brand-Name Concepts

  • Terazosin 1 MG/ML [Tezruly] SBDC · 2689135
  • Terazosin Oral Solution [Tezruly] SBDF · 2689138
  • Tezruly Oral Liquid Product SBDG · 2689137
  • Tezruly Oral Product SBDG · 2689136
  • Tezruly BN · 2689134

📦 FDA Products & Package NDCs

1 product · 1 package NDC
1 package NDC map to RxCUI 2689139 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
70954-0592-10 150 mL in 1 BOTTLE (70954-592-10) TEZRULY ANI Pharmaceuticals, Inc. 2025-04-18
Observed labelers: ANI Pharmaceuticals, Inc. (1) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.